Cell and Gene Therapy International Content Hub
Expert insights, founder journeys, and thought leadership in Cell and Gene Therapy, Cell Therapy Manufacturing, and Cell Culture Processing—where innovation meets expertise.
Start Up Stories
Discover the innovative biotech startups reshaping healthcare's future—their bold visions, breakthrough technologies, and the passionate founders behind them.
Aurion Biotech is a pioneering clinical-stage company developing cell therapies for vision restoration. Our revolutionary technology creates up to 1,000 treatments from a single donor cornea, addressing the critical global shortage of transplantable tissue.
Discover the innovative journey of Nanite Inc, a groundbreaking company combining AI-driven polymer design with multiplexed in vivo screening to develop best-in-class nanoparticles engineered for tissue-specific delivery.
This interview features Eric Halioua, CEO of PDCline Pharma, discussing his journey in founding and developing a biotechnology company focused on innovative cancer vaccines. Eric shares his background in the biotech industry, the founding story of PDCline Pharma, and the company's development of a novel therapeutic platform using a unique dendritic cell line to stimulate immune responses against cancer.
This interview features David Howell, co-founder of Bondwell Technologies, a startup developing revolutionary protein-based biomaterials. Founded in 2017 by Texas A&M University scientists and headquartered in College Station, TX, the company is commercializing a unique platform technology with applications across energy, environment, and medicine.
Exploring Cell & Gene Therapy Innovation: Key Topics at Our Upcoming Event
How are advanced bioprocessing techniques revolutionizing cell therapy manufacturing?
Advanced bioprocessing techniques are transforming cell therapy manufacturing through automation, closed systems, and continuous manufacturing processes that enhance efficiency while reducing contamination risks. Single-use technologies improve flexibility, while process analytical technologies enable real-time monitoring for consistent quality control. AI and machine learning integration optimizes manufacturing parameters and enables predictive modelling for improved outcomes.
Join the "Lunch & Learn" session where leading technology providers showcase the latest advancements in bioprocessing, offering insights into breakthrough technologies designed to enhance efficiency, scalability, and innovation in biomanufacturing.
What strategies are driving the transition from adherent to suspension cell culture systems?
The transition to suspension culture systems relies on sophisticated cell adaptation protocols, specialized media formulations, and novel bioreactor designs that optimize fluid dynamics. Genetic engineering approaches modify cellular attachment properties, while microcarrier technologies serve as intermediate solutions by providing attachment surfaces within suspension environments.
Attend the "Strategies for Cell Therapy Manufacturing" track on Day Two of Cell & Gene Therapy International, which covers innovations in cell culture systems including the transition from adherent to suspension cultures.
How is artificial intelligence transforming cell and gene therapy manufacturing in 2025?
AI is revolutionizing cell and gene therapy manufacturing by addressing one of the industry's greatest challenges: manufacturing consistency. Advanced algorithms are now enabling real-time process optimization, predictive quality control, and automated decision-making that significantly reduces variability while enhancing product quality. These AI-driven approaches are particularly valuable for autologous therapies where traditional economies of scale don't apply.
Attend this session to discover how artificial intelligence is revolutionizing cell and gene therapy manufacturing through real-time process optimization, predictive quality control, and automated decision-making systems that significantly reduce variability while enhancing product quality—particularly valuable for autologous therapies where traditional economies of scale don't apply.
What progress is being made in decentralized manufacturing models for personalized cell therapies?
Decentralized manufacturing is gaining significant momentum as a solution to bring production closer to patients, dramatically reducing logistics challenges and treatment delays. The industry is seeing innovative approaches combining modular facilities, standardized protocols, and sophisticated quality control systems that maintain regulatory compliance while enabling point-of-care manufacturing. This shift is particularly critical for time-sensitive autologous therapies where patient outcomes depend on rapid processing.
Attend this session to discover innovative approaches combining modular facilities, standardized protocols, and sophisticated quality control systems that maintain regulatory compliance while enabling point-of-care manufacturing—a critical advancement for time-sensitive autologous therapies where patient outcomes depend on rapid processing.
How are real-time analytics transforming quality control in cell and gene therapy production?
Advanced inline and online analytics are revolutionizing quality control by enabling continuous monitoring throughout the manufacturing process rather than relying solely on end-product testing. These technologies, coupled with machine learning algorithms, allow for real-time adjustments that maintain product quality while reducing production time and costs—a critical advancement for therapies with complex quality attributes.
Attend this session to discover how advanced inline and online analytics coupled with machine learning algorithms are enabling continuous monitoring throughout the manufacturing process, allowing for real-time adjustments that maintain product quality while reducing production time and costs—a critical advancement for therapies with complex quality attributes.
